Histoplasmosis in solid organ transplant recipients

Clinical Infectious Diseases

Volumn 50, Issue 1, 2010, Pages 122-123

  Hage, Chadi ^a   Kleiman, Martin B ^a   Wheat, L Joseph ^b  

^a INDIANA UNIVERSITY   (United States)

^b MIRAVISTA DIAGNOSTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE;

ANTIGEN DETECTION; BLOOD CULTURE; DRUG EFFICACY; FUNGUS CULTURE; HIGH RISK PATIENT; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; LETTER; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL;

HISTOPLASMOSIS; HUMANS; ORGAN TRANSPLANTATION;

EID: 72049093520     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649056     Document Type: Letter

References (5)

1. Cuellar-Rodriguez J, Avery RK, Lard M, et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis 2009; 49(5):710-716
2. Straub M, Schwarz J. The healed primary complex in histoplasmosis. Am J Clin Pathol 1955; 25(7):727-741
3. Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis 2002; 4(3): 148-151 (Pubitemid 35364779)
4. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969; 99(Suppl):1-132.
5. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003; 167(9):1279-1282 (Pubitemid 36555102)